J Thromb Haemost: Anticoagulant therapy in patients with severe COVID-19 is associated with reduced mortality

The relatively high mortality rate for severe coronavirus disease (COVID-19) in 2019 is a cause for concern, and experts unanimously recommend the application of heparin in patients with COVID-19 due to the risk of diffuse intravascular clotting and venous thromboembolismHowever, its effectiveness has yet to be verifiedrecently published a study in journal Sthrombosis and Haemostasis, an authoritative journal of thrombosis and clotting disease, in which researchers reviewed the results, medication and prognosis of patients in Tongji Hospital who were continuously diagnosed with severe COVID-19, compared the 28-day mortality rates of heparin users and heparin non-users, and compared the risk of coagulation disorders (SIC) induced by sepsisthe study included 449 patients with severe COVID-19, of which 99 were treated with heparin for 7 days or more (mainly low-molecular heparin, LMWH)Multivariate analysis showed a positive correlation between D-difile, clotted entogenic time and age with 28-day mortality, while platelet count was negatively correlated with 28-day mortalityThere was no difference in 28-day mortality rates between heparin users and non-users (30.3% vs 29.7%, P-0.910)However, in patients with an SIC score of 4 (40.0% vs 64.2%, P-0.029) or D dipolymer s.6 times the upper limit of normal values (32.8% vs 52.4%, P-0.017), the 28-day mortality rate for heparin users was lower than in unused patientsit can be seen that patients with severe COVID-19 who met the SIC standard or D-dipolymer significantly increased were given low-molecular heparin-based anticoagulant therapy to obtain a better prognosis